Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities | Nefrología
Study design. Steroid dose will be at least 5 mg prednisolone or... | Download Scientific Diagram
Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study - American Journal of Transplantation
Recommendations of everolimus use in liver transplant | Gastroenterología y Hepatología (English Edition)
De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study - American Journal of Transplantation
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities | Nefrología
![PDF] Introduction of everolimus in kidney transplant recipients at a late posttransplant stage | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/52b7f3e549ab8e70c2079418becddcf9e9535b89/3-Table1-1.png "PDF] Introduction of everolimus in kidney transplant recipients at a late posttransplant stage | Semantic Scholar")
PDF] Introduction of everolimus in kidney transplant recipients at a late posttransplant stage | Semantic Scholar
Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions - ScienceDirect
Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de
Full article: The use of everolimus in renal-transplant patients
Enhanced Humoral Immune Response After COVID-19 Vaccination... : Transplantation
Frontiers | Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies - ATC Abstracts
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect
IJMS | Free Full-Text | Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients - ScienceDirect
Article: Conversion from tacrolimus to everolimus with complete and early glucocorticoid withdrawal after kidney transplantation: a randomised trial (full text) - January 2018 - NJM
Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study - ATC Abstracts
Everolimus Dosage Guide + Max Dose, Adjustments - Drugs.com
An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients - ScienceDirect
Article: Conversion from tacrolimus to everolimus with complete and early glucocorticoid withdrawal after kidney transplantation: a randomised trial (full text) - January 2018 - NJM
Use of everolimus in liver transplantation
Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review | SpringerLink
Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial - American Journal of Transplantation
